Using targeted genetic approaches, an efficient and durable NIPA knockdown of more than 70% was achieved in the murine IL-3 dependent Ba/F3 cell line and the human ALCL cell line Karpas299 (Figure 1C). The gene discussed is IL3; the disease is anaplastic large cell lymphoma.